NCT00769145

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 18 Years – 110 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.

Detailed description

As a secondary objective, this study also aims to establish the corneal and anterior chamber concentration of ranibizumab when delivered subconjunctivally at the limbus in patients undergoing corneal transplantation. The effects of ranibizumab on corneal epithelial healing will be examined following adjunctive use in corneal transplantation. Finally, clinical characteristics including recurrent corneal neovascularization will be studied.

Conditions

• Corneal Neovascularization

Interventions

Type	Name	Description
DRUG	Ranibizumab	0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).

Timeline

• Start date: 2008-10-01
• Primary completion: 2011-08-01
• Completion: 2012-03-01
• First posted: 2008-10-08
• Last updated: 2017-07-11

Locations

1 site across 1 country: United States